Description
Chonluten is a synthetic tripeptide bioregulator with the sequence Glu-Asp-Gly (EDG), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is the respiratory system representative of the Khavinson bioregulator series — targeting bronchopulmonary epithelial cells with the same intranuclear DNA-binding mechanism that characterizes the broader peptide class. Chonluten enters bronchial epithelial cell nuclei and binds specific promoter regions, modulating the expression of stress-response and inflammatory genes, including c-Fos, HSP70, SOD, COX-2, and TNF-alpha in respiratory tissue models. This gene-level targeting distinguishes it from receptor-mediated respiratory research tools and positions it as a tool for studying bronchopulmonary epithelial gene regulation directly. Researchers working across the Khavinson specialty research peptide series often include Chonluten alongside tissue-specific bioregulators targeting other organ systems.
Key Characteristics
- Targets bronchopulmonary epithelium with tissue specificity — preclinical data documents modulation of oxidative stress markers, mucosal barrier proteins, and inflammatory mediators in respiratory epithelial cell populations
- Regulates SOD (superoxide dismutase) expression, connecting Chonluten research to redox biology and oxidative stress modeling in lung tissue — a distinct research angle from its inflammatory gene targets
- ERK1/2 and JNK kinase activation has been documented in preclinical models, linking Chonluten to MAP kinase signaling pathways involved in epithelial cell proliferation and stress adaptation
- Shares the Khavinson epigenetic mechanism with Cartalax (cartilage) and Cardiogen (cardiac), but the tissue target and gene expression profile are entirely distinct — researchers building multi-tissue bioregulator models use each compound separately for its organ-specific activity
- All published evidence is preclinical; the evidence base is concentrated within the Khavinson research network with no independent Western clinical trials
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. As a tripeptide, Chonluten is susceptible to rapid proteolytic degradation under suboptimal conditions. Reconstitute immediately before use and avoid repeated freeze-thaw cycles.
FAQs
What is Chonluten?
Chonluten (EDG) is a synthetic tripeptide bioregulator from the Khavinson series, developed for bronchopulmonary epithelial research. It targets respiratory epithelial cell nuclei and modulates gene expression of stress-response markers, antioxidant enzymes, and inflammatory mediators, including SOD, c-Fos, HSP70, and COX-2. All published evidence is preclinical.
How does Chonluten differ from other respiratory research peptides?
Most respiratory research peptides work through cell-surface receptors or second messenger cascades. Chonluten acts intranuclearly — it enters epithelial cells and directly modulates gene promoter activity. Its gene targets center on oxidative stress response and inflammatory signaling rather than structural airway biology, which gives it a distinct experimental role from compounds that work through airway smooth muscle receptors or mucociliary pathway agonism.
How does Chonluten relate to other Khavinson respiratory bioregulators?
Chonluten (EDG) targets bronchopulmonary epithelial cells and focuses on stress-response and inflammatory gene regulation. It is distinct from Bronchogen (AEDL), another Khavinson respiratory bioregulator that primarily activates epithelial differentiation genes, including NKX2-1, FOXA1, and mucin production markers. The two compounds address different aspects of respiratory epithelial biology and appear together in some Khavinson multi-compound research protocols precisely because their gene targets don’t overlap.
